Abdul Mannan: A Clinical Framework for Direct Oral Anticoagulant Reversal in Acute Bleeding
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“Four TSOACs.
Four different clearance profiles.
One wrong decision at 2am in A and E.
This is for every registrar who has been in that position.
You know the drugs.
- Dabigatran.
- Rivaroxaban.
- Apixaban.
- Edoxaban.
But when someone is bleeding in front of you, knowing the name is not enough.
You need the number, the mechanism, and the right reversal agent.
In that order.
Here is what I want every trainee to have locked in:
Dabigatran is 80 percent renal. AKI doubles or triples the half-life.
It is the one TSOAC you can dialyse.
Idarucizumab 5 gram IV is your first call.
If it is not available, aPCC (FEIBA) 80 U/kg. Not 50. Not FFP. 80.
Rivaroxaban and Apixaban bleed?
Andexanet Alfa is your specific reversal agent.
But NICE TA697 (updated January 2025) restricts its use to GI tract life-threatening bleeds only.
ICH, retroperitoneal, surgical bleeds? 4F-PCC 50 U/kg.
Edoxaban is 50 percent renal.
Andexanet Alfa is not NICE-approved for it. 4F-PCC 50 U/kg. Full stop.
FFP reverses nothing here. Not Dabigatran. Not any Xa inhibitor. Put it down.
One clinical pearl that trips people up every time: Edoxaban is contraindicated in AF when CrCl goes above 95 mL/min.
Too fast clearance. Subtherapeutic levels. Paradoxical stroke risk. No other TSOAC behaves this way.
I built a free interactive dashboard covering all four drugs.
Pharmacokinetics. Lab interpretation matrix (because a normal PT does NOT rule out Apixaban).
Reversal protocols with the NICE TA697 restriction clearly flagged.
A self-assessment quiz that reshuffles every single attempt and maps your weak spots at the end.
Browser-based. Light and dark mode.
No login. No paywall.
Which part of TSOAC reversal do you find trainees get wrong most often?”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow